#USA #San Diego #Viking Therapeutics #Obesity Treatments #VK2735

Viking Therapeutics Reports Second Quarter 2026 Financial Results

On July 29, 2026, Viking Therapeutics, Inc. (Nasdaq: VKTX), a biopharmaceutical company dedicated to innovative therapies for metabolic disorders, revealed key financial figures for Q2 2026. The announcement included updates on its clinical pipeline and corporate strategies, showcasing the company's commitment to advancing treatments for obesity.

Financial Performance

For the second quarter of 2026, Viking's research and development expenses surged to $115.8 million, reflecting a significant increase from $60.2 million in the previous year. This rise was primarily attributable to escalated expenses linked to clinical trials, salaries, and consulting services. General and administrative costs also rose to $16.9 million, compared to $14.4 million in Q2 2025.

The reported net loss for this quarter reached $128.0 million, or $1.10 per share, signaling a downturn from a loss of $65.6 million, or $0.58 per share, during the same period in 2025.

Clinical Pipeline Advancements

Under the leadership of CEO Brian Lian, Ph.D., Viking has made notable progress in its clinical trials, particularly the Phase 3 trials for VK2735, the company's flagship compound aimed at treating obesity. Noteworthy highlights include:

• - Full enrollment of the Phase 3 VANQUISH-1 and VANQUISH-2 trials.
• - Plans to initiate trials for an oral version of VK2735 in Q4 2026, aiming to offer a pioneering oral dual GLP-1/GIP agonist formulation.
• - Positive preliminary results from previous phases indicating significant body weight reduction with VK2735, including a notable 14.7% reduction in mean body weight observed in the Phase 2 VENTURE trial.

Additionally, Viking has begun a Phase 1 study for VK3019, an investigational amylin receptor agonist, which may provide an important new therapy option for obesity management.

Strategic Corporate Developments

In tandem with clinical advancements, Viking has been bolstering its internal infrastructure. The appointment of Dr. Hubert Chen as Chief Medical Officer illustrates Viking's investment in expanding its expertise. With over 20 years in various senior roles, Dr. Chen's addition is anticipated to significantly enhance Viking's drug development processes.

Furthermore, Viking’s balance sheet remains robust, with $502 million in cash at the end of June 2026. This strong financial positioning will facilitate continued investment in its expansive and innovative pipeline, which aims to transform obesity treatment paradigms.

Looking Forward

The upcoming months hold promise as Viking prepares for critical trial initiate for its oral VK2735 formulation and the ongoing maintenance dosing studies, with expected data release scheduled for Q3 2026. With both oral and injectable options on the horizon, Viking is strategically positioned to offer flexible therapy solutions to meet diverse patient needs, ultimately aiming to improve patient health outcomes across metabolic disorders.

As Viking Therapeutics demonstrates momentum in its clinical capacities and strategic maneuvers, it remains on track to make significant contributions to obesity treatment options, further reinforcing its standing in the biopharmaceutical landscape.